EU stem cell funding in jeopardy?

A handful of nations seek a ban even in countries where the research is legal

Written byNed Stafford
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share
Germany, Austria and other nations opposed to EU funding of human embryonic stem cell research proposed an EU funding ban this month in Brussels at a meeting of the EU's 25 national science ministers, raising concerns that the minority group could force nations to remove this funding from the newest budget, even for scientists in countries where the research is legal.The six nations -- including also Italy, Poland, Malta and Slovakia -- failed to win additional backing at the meeting for a funding ban, but do hold enough combined voting power in the Council of science ministers to form a so-called "blocking minority." This means they could halt enactment of the EU's next science funding program for 2007-13, known as Framework Programme 7 (FP7), unless wording is added to the final FP7 document that would ban EU funding of human embryonic stem cell research.Under Framework Programme 6 (FP6) guidelines, the EU gives funding priority to human adult stem cell research and will not fund any research on embryonic stem cells conducted in member states that forbid the research. Under FP6, eight projects involving human embryonic stem cell research have been funded and nearly 100 involving human adult stem cells have received funding approval, said Antonia Mochan, spokeswoman for EU Research Commissioner Janez Potocnik.Mochan told The Scientist that Potocnik has recommended that current guidelines pertaining to funding of human embryonic stem cell research in FP6 be retained in FP7. Although the six nations oppose this proposal, 15 nations agree, and four are neutral. Before any FP7 money for research can start flowing, a final plan must be approved by a qualified majority of the Council's 25 science ministers and also by the European Parliament.Daniel Pipeleers, professor at Brussels Free University-VUB and director of the JDRF Center for Beta Cell Therapy in Diabetes, which will receive about ?1 million from the EU in direct support of human embryonic stem cell research from 2005-10 under FP6 guidelines, told The Scientist that he is concerned. (According to Mochan, already-approved FP6 money would not be affected by changes in FP7.)Pipeleers added that a small group of nations should not impose a minority opinion on the EU. "I don't think they can decide for the whole EU," he said, adding that successful research in human embryonic stem cells requires collaboration among scientists across the EU, involving also teams working on adult stem cells, as well as ethicists. "Trying to block EU incentives and support for such European scientific collaboration goes too far."This is a familiar situation to EU scientists -- opponents of human embryonic stem cell research actively sought an EU funding ban in FP6, Pipeleers said, but eventually accepted the current guidelines. They might not give up as easily this time, he added.In an interview with The Scientist, Florian Frank, a spokesman for Germany's new Minister of Education and Research, Annette Schavan, who strongly opposes human embryonic stem cell research, said that Germany's position is that EU funding should not be used for research projects that are not legal in Germany, even if those projects take place in other countries. If EU money is being used to support research not legal in Germany, "then we have something to say about it," he said.Frank added that Germany would continue trying to convince other nations to accept this position. "This is politics. You try to convince the others." However, he declined to say if Germany would form a blocking minority if the FP7 does not ban EU funding for human embryonic stem cell research.Ned Stafford nstafford@the-scientist.comEU blocking minority http://europa.eu.int/abc/12lessons/index4_en.htmJanez Potocnik http://europa.eu.int/comm/commission_barroso/potocnik/indexfl_en.htmS. Pincock, "EU promises funding deal," The Scientist, February 2, 2006 http://www.the-scientist.com/news/display/23036/Daniel Pipeleers http://www.betacelltherapy.org/N/029_investigators_D.php?ref=17697285&idBis=12733&rfr=029_investigators_L.php&user=JDRF Center for Beta Cell Therapy in Diabetes http://www.betacelltherapy.org/Brussels Free University http://www.vub.ac.be/english/index.phpAnnette Schavan http://www.bmbf.de/en/index.phpN. Stafford, "German minister rebukes stem cell research," The Scientist, January 5, 2006 http://www.the-scientist.com/news/display/22923/
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies